Annual FCF
-$31.41 M
+$144.77 M+82.17%
31 December 2023
Summary:
TG Therapeutics annual free cash flow is currently -$31.41 million, with the most recent change of +$144.77 million (+82.17%) on 31 December 2023. During the last 3 years, it has risen by +$183.45 million (+85.38%). TGTX annual FCF is now -36173.67% below its all-time high of -$86.60 thousand, reached on 31 December 2011.TGTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$12.23 M
-$17.77 M-320.90%
30 September 2024
Summary:
TG Therapeutics quarterly free cash flow is currently -$12.23 million, with the most recent change of -$17.77 million (-320.90%) on 30 September 2024. Over the past year, it has dropped by -$95.93 million (-114.61%). TGTX quarterly FCF is now -114.61% below its all-time high of $83.70 million, reached on 30 September 2023.TGTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$28.11 M
-$95.93 M-141.45%
30 September 2024
Summary:
TG Therapeutics TTM free cash flow is currently -$28.11 million, with the most recent change of -$95.93 million (-141.45%) on 30 September 2024. Over the past year, it has increased by +$13.97 million (+33.19%). TGTX TTM FCF is now -141.45% below its all-time high of $67.82 million, reached on 30 June 2024.TGTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TGTX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +82.2% | -114.6% | +33.2% |
| 3 y3 years | +85.4% | +81.8% | +89.2% |
| 5 y5 years | +75.7% | +63.2% | +79.4% |
TGTX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +89.4% | -114.6% | +85.9% | -141.4% | +90.5% |
| 5 y | 5 years | at high | +89.4% | -114.6% | +85.9% | -141.4% | +90.5% |
| alltime | all time | <-9999.0% | +89.4% | -114.6% | +85.9% | -141.4% | +90.5% |
TG Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$12.23 M(-320.9%) | -$28.11 M(-141.4%) |
| June 2024 | - | $5.54 M(-167.5%) | $67.82 M(+234.4%) |
| Mar 2024 | - | -$8.21 M(-37.9%) | $20.28 M(-164.6%) |
| Dec 2023 | -$31.41 M(-82.2%) | -$13.21 M(-115.8%) | -$31.41 M(-25.3%) |
| Sept 2023 | - | $83.70 M(-299.3%) | -$42.08 M(-73.7%) |
| June 2023 | - | -$42.01 M(-29.9%) | -$160.28 M(-4.2%) |
| Mar 2023 | - | -$59.90 M(+150.9%) | -$167.39 M(-5.0%) |
| Dec 2022 | -$176.18 M(-40.5%) | -$23.87 M(-30.8%) | -$176.18 M(-26.4%) |
| Sept 2022 | - | -$34.50 M(-29.8%) | -$239.30 M(-12.0%) |
| June 2022 | - | -$49.12 M(-28.5%) | -$272.08 M(-4.0%) |
| Mar 2022 | - | -$68.70 M(-21.0%) | -$283.31 M(-4.3%) |
| Dec 2021 | -$296.04 M(+37.8%) | -$86.99 M(+29.3%) | -$296.04 M(+13.3%) |
| Sept 2021 | - | -$67.28 M(+11.5%) | -$261.23 M(+4.3%) |
| June 2021 | - | -$60.34 M(-25.9%) | -$250.57 M(+7.0%) |
| Mar 2021 | - | -$81.42 M(+56.0%) | -$234.10 M(+9.0%) |
| Dec 2020 | -$214.86 M(+61.6%) | -$52.18 M(-7.8%) | -$214.86 M(+11.3%) |
| Sept 2020 | - | -$56.62 M(+29.0%) | -$193.11 M(+13.8%) |
| June 2020 | - | -$43.88 M(-29.4%) | -$169.76 M(+4.9%) |
| Mar 2020 | - | -$62.18 M(+104.4%) | -$161.75 M(+21.7%) |
| Dec 2019 | -$132.94 M(+3.0%) | -$30.43 M(-8.5%) | -$132.94 M(-2.4%) |
| Sept 2019 | - | -$33.27 M(-7.3%) | -$136.21 M(+0.2%) |
| June 2019 | - | -$35.88 M(+7.5%) | -$135.97 M(+1.2%) |
| Mar 2019 | - | -$33.37 M(-1.0%) | -$134.31 M(+4.1%) |
| Dec 2018 | -$129.01 M(+37.6%) | -$33.70 M(+2.0%) | -$129.01 M(+10.1%) |
| Sept 2018 | - | -$33.03 M(-3.5%) | -$117.17 M(+9.6%) |
| June 2018 | - | -$34.22 M(+21.9%) | -$106.91 M(+7.4%) |
| Mar 2018 | - | -$28.07 M(+28.4%) | -$99.53 M(+6.1%) |
| Dec 2017 | -$93.76 M(+51.4%) | -$21.86 M(-4.0%) | -$93.76 M(+5.4%) |
| Sept 2017 | - | -$22.77 M(-15.1%) | -$88.95 M(+9.5%) |
| June 2017 | - | -$26.83 M(+20.3%) | -$81.23 M(+20.7%) |
| Mar 2017 | - | -$22.30 M(+30.9%) | -$67.28 M(+8.6%) |
| Dec 2016 | -$61.93 M(+38.4%) | -$17.04 M(+13.2%) | -$61.93 M(+7.2%) |
| Sept 2016 | - | -$15.06 M(+16.9%) | -$57.77 M(+8.2%) |
| June 2016 | - | -$12.88 M(-24.0%) | -$53.42 M(+1.2%) |
| Mar 2016 | - | -$16.96 M(+31.6%) | -$52.80 M(+18.0%) |
| Dec 2015 | -$44.73 M(+27.5%) | -$12.88 M(+20.4%) | -$44.73 M(-4.8%) |
| Sept 2015 | - | -$10.70 M(-12.8%) | -$46.97 M(+6.0%) |
| June 2015 | - | -$12.26 M(+37.9%) | -$44.32 M(+24.4%) |
| Mar 2015 | - | -$8.89 M(-41.2%) | -$35.64 M(+1.6%) |
| Dec 2014 | -$35.08 M(+226.5%) | -$15.12 M(+87.8%) | -$35.08 M(+41.5%) |
| Sept 2014 | - | -$8.05 M(+125.4%) | -$24.78 M(+38.6%) |
| June 2014 | - | -$3.57 M(-57.1%) | -$17.89 M(+6.0%) |
| Mar 2014 | - | -$8.33 M(+72.6%) | -$16.87 M(+57.0%) |
| Dec 2013 | -$10.74 M(+107.1%) | -$4.83 M(+317.7%) | -$10.74 M(+59.1%) |
| Sept 2013 | - | -$1.16 M(-54.8%) | -$6.75 M(-21.4%) |
| June 2013 | - | -$2.56 M(+16.0%) | -$8.59 M(+31.5%) |
| Mar 2013 | - | -$2.20 M(+164.6%) | -$6.53 M(+25.9%) |
| Dec 2012 | -$5.19 M(+5892.4%) | -$833.30 K(-72.2%) | -$5.19 M(+17.6%) |
| Sept 2012 | - | -$2.99 M(+497.2%) | -$4.41 M(+204.4%) |
| June 2012 | - | -$501.20 K(-41.8%) | -$1.45 M(<-9900.0%) |
| Mar 2012 | - | -$861.60 K(+1425.0%) | $0.00(-100.0%) |
| Dec 2011 | -$86.60 K(-95.6%) | -$56.50 K(+87.7%) | -$86.60 K(-84.9%) |
| Sept 2011 | - | -$30.10 K(-103.2%) | -$571.80 K(-40.1%) |
| June 2011 | - | $948.20 K(-200.0%) | -$954.40 K(-58.8%) |
| Mar 2011 | - | -$948.20 K(+75.0%) | -$2.32 M(+17.4%) |
| Dec 2010 | -$1.97 M | -$541.70 K(+31.3%) | -$1.97 M(+12.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$412.70 K(-0.2%) | -$1.76 M(+18.3%) |
| June 2010 | - | -$413.70 K(-31.6%) | -$1.49 M(+47.4%) |
| Mar 2010 | - | -$604.80 K(+84.9%) | -$1.01 M(-3.9%) |
| Dec 2009 | -$1.05 M(-76.4%) | -$327.10 K(+132.2%) | -$1.05 M(-36.1%) |
| Sept 2009 | - | -$140.90 K(-319.8%) | -$1.64 M(-22.6%) |
| June 2009 | - | $64.10 K(-109.9%) | -$2.12 M(-41.7%) |
| Mar 2009 | - | -$645.80 K(-29.8%) | -$3.64 M(-18.3%) |
| Dec 2008 | -$4.45 M(-56.5%) | -$919.80 K(+48.3%) | -$4.45 M(-9.4%) |
| Sept 2008 | - | -$620.30 K(-57.3%) | -$4.92 M(-30.3%) |
| June 2008 | - | -$1.45 M(-0.7%) | -$7.05 M(-25.9%) |
| Mar 2008 | - | -$1.46 M(+5.7%) | -$9.51 M(-7.1%) |
| Dec 2007 | -$10.24 M(+31.5%) | -$1.38 M(-49.8%) | -$10.24 M(-0.1%) |
| Sept 2007 | - | -$2.76 M(-29.6%) | -$10.25 M(+6.5%) |
| June 2007 | - | -$3.91 M(+78.9%) | -$9.62 M(+17.5%) |
| Mar 2007 | - | -$2.19 M(+57.4%) | -$8.19 M(+5.2%) |
| Dec 2006 | -$7.79 M(+23.9%) | -$1.39 M(-34.8%) | -$7.79 M(-8.1%) |
| Sept 2006 | - | -$2.13 M(-14.1%) | -$8.48 M(+9.1%) |
| June 2006 | - | -$2.48 M(+39.1%) | -$7.77 M(+14.8%) |
| Mar 2006 | - | -$1.78 M(-14.2%) | -$6.77 M(+7.7%) |
| Dec 2005 | -$6.28 M(+7.8%) | -$2.08 M(+45.8%) | -$6.28 M(+1.2%) |
| Sept 2005 | - | -$1.43 M(-3.7%) | -$6.21 M(-1.5%) |
| June 2005 | - | -$1.48 M(+14.1%) | -$6.30 M(+8.4%) |
| Mar 2005 | - | -$1.30 M(-35.1%) | -$5.81 M(-0.3%) |
| Dec 2004 | -$5.83 M(+68.6%) | -$2.00 M(+31.8%) | -$5.83 M(+5.2%) |
| Sept 2004 | - | -$1.52 M(+53.0%) | -$5.54 M(+21.9%) |
| June 2004 | - | -$993.00 K(-24.5%) | -$4.55 M(+7.7%) |
| Mar 2004 | - | -$1.31 M(-23.4%) | -$4.22 M(+22.1%) |
| Dec 2003 | -$3.46 M(+351.6%) | -$1.72 M(+226.9%) | -$3.46 M(+160.0%) |
| Sept 2003 | - | -$524.70 K(-21.5%) | -$1.33 M(-10.1%) |
| June 2003 | - | -$668.70 K(+21.7%) | -$1.48 M(+112.8%) |
| Mar 2003 | - | -$549.40 K(-233.1%) | -$695.40 K(-9.2%) |
| Dec 2002 | -$765.70 K(-83.3%) | $412.80 K(-161.2%) | -$765.70 K(-61.1%) |
| Sept 2002 | - | -$674.50 K(-683.0%) | -$1.97 M(+4.5%) |
| June 2002 | - | $115.70 K(-118.7%) | -$1.88 M(-31.3%) |
| Mar 2002 | - | -$619.70 K(-21.4%) | -$2.74 M(-40.3%) |
| Dec 2001 | -$4.58 M(+246.0%) | -$788.80 K(+33.8%) | -$4.58 M(+97.6%) |
| Sept 2001 | - | -$589.40 K(-20.4%) | -$2.32 M(-5.4%) |
| June 2001 | - | -$740.00 K(-70.0%) | -$2.45 M(-27.1%) |
| Mar 2001 | - | -$2.46 M(-267.1%) | -$3.36 M(+153.6%) |
| Dec 2000 | -$1.32 M(-44.8%) | $1.48 M(-304.6%) | -$1.32 M(-55.8%) |
| Sept 2000 | - | -$720.90 K(-56.3%) | -$3.00 M(+12.0%) |
| June 2000 | - | -$1.65 M(+283.6%) | -$2.68 M(+38.8%) |
| Mar 2000 | - | -$429.80 K(+114.9%) | -$1.93 M(-16.1%) |
| Dec 1999 | -$2.40 M(-14.3%) | -$200.00 K(-50.0%) | -$2.30 M(-30.3%) |
| Sept 1999 | - | -$400.00 K(-55.6%) | -$3.30 M(-21.4%) |
| June 1999 | - | -$900.00 K(+12.5%) | -$4.20 M(+100.0%) |
| Mar 1999 | - | -$800.00 K(-33.3%) | -$2.10 M(-25.0%) |
| Dec 1998 | -$2.80 M(-34.9%) | -$1.20 M(-7.7%) | -$2.80 M(0.0%) |
| Sept 1998 | - | -$1.30 M(-208.3%) | -$2.80 M(+3.7%) |
| June 1998 | - | $1.20 M(-180.0%) | -$2.70 M(-46.0%) |
| Mar 1998 | - | -$1.50 M(+25.0%) | -$5.00 M(+16.3%) |
| Dec 1997 | -$4.30 M(+4.9%) | -$1.20 M(0.0%) | -$4.30 M(+38.7%) |
| Sept 1997 | - | -$1.20 M(+9.1%) | -$3.10 M(+63.2%) |
| June 1997 | - | -$1.10 M(+37.5%) | -$1.90 M(+137.5%) |
| Mar 1997 | - | -$800.00 K | -$800.00 K |
| Dec 1996 | -$4.10 M | - | - |
FAQ
- What is TG Therapeutics annual free cash flow?
- What is the all time high annual FCF for TG Therapeutics?
- What is TG Therapeutics annual FCF year-on-year change?
- What is TG Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for TG Therapeutics?
- What is TG Therapeutics quarterly FCF year-on-year change?
- What is TG Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for TG Therapeutics?
- What is TG Therapeutics TTM FCF year-on-year change?
What is TG Therapeutics annual free cash flow?
The current annual FCF of TGTX is -$31.41 M
What is the all time high annual FCF for TG Therapeutics?
TG Therapeutics all-time high annual free cash flow is -$86.60 K
What is TG Therapeutics annual FCF year-on-year change?
Over the past year, TGTX annual free cash flow has changed by +$144.77 M (+82.17%)
What is TG Therapeutics quarterly free cash flow?
The current quarterly FCF of TGTX is -$12.23 M
What is the all time high quarterly FCF for TG Therapeutics?
TG Therapeutics all-time high quarterly free cash flow is $83.70 M
What is TG Therapeutics quarterly FCF year-on-year change?
Over the past year, TGTX quarterly free cash flow has changed by -$95.93 M (-114.61%)
What is TG Therapeutics TTM free cash flow?
The current TTM FCF of TGTX is -$28.11 M
What is the all time high TTM FCF for TG Therapeutics?
TG Therapeutics all-time high TTM free cash flow is $67.82 M
What is TG Therapeutics TTM FCF year-on-year change?
Over the past year, TGTX TTM free cash flow has changed by +$13.97 M (+33.19%)